Journal
NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-06134-z
Keywords
-
Categories
Funding
- MiCareo Taiwan Co., Ltd.
- Division of Experimental Surgery of the Department of Surgery, Taipei Veterans General Hospital
- Ministry of Science and Technology [104-2321-B-010-005, 104-0210-01-09-02, 107-0210-01-19-01]
- National Health Research Institutes [NHRI-EX107-10622BI]
- Taipei Veterans General Hospital [V107C-071, V107D32-001-MY2-1, VTA107-V1-3-2]
- Featured Areas Research Center Program within the Ministry of Education
- Ministry of Health and Welfare, Center of Excellence for Cancer Research [MOHW107-TDU-B-211-114019]
- Chang-Gung Memorial Hospital [CMRPG 6E0281, CORPG 6B0373]
Ask authors/readers for more resources
The motile characteristics and mechanisms that drive the dissemination of diffuse large B-cell lymphoma (DLBCL) are elusive. Here, we show that DLBCL initiates dissemination through activating STAT3-mediated amoeboid migration. Mechanistically, STAT3 activates RHOH transcription, which competes with the RhoGDP dissociation inhibitor RhoGDly to activate RhoA. In addition, activated STAT3 regulates microtubule dynamics and releases ARHGEF2 to activate RhoA. Both the JAK inhibitor ruxolitinib and the microtubule stabilizer Taxol suppress DLBCL cell dissemination in vivo. A clinical DLBCL sample analysis shows that STAT3-driven amoeboid movement is particularly important for the transition from stage I to stage II. This study elucidates the mechanism of DLBCL dissemination and progression and highlights the potential of combating advanced DLBCL with a JAK/STAT inhibitor or microtubule stabilizer to reduce DLBCL motility; these findings may have a great impact on the development of patient-tailored treatments for DLBCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available